Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT ID: NCT03486873
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
3500 participants
INTERVENTIONAL
2018-08-21
2043-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment.
Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab 200 mg
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants.
Pembrolizumab
200 or 400 mg IV infusion
Pembrolizumab 400 mg
Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants.
Pembrolizumab
200 or 400 mg IV infusion
Pembrolizumab 200 mg + SOC: Per Parent Study)
Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle PLUS standard of care (SOC) treatment (or per parent study if there is no SOC) for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
Pembrolizumab
200 or 400 mg IV infusion
Standard of Care (SOC)
IV infusion or oral tablets
Pembrolizumab 400 mg + SOC (Per Parent Study)
Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle PLUS SOC treatment (or per parent study if there is no SOC) for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
Pembrolizumab
200 or 400 mg IV infusion
Standard of Care (SOC)
IV infusion or oral tablets
SOC (Per Parent Study)
Participants receive the dose matched non-pembrolizumab SOC treatment (e.g. chemotherapy) they were receiving as per parent study protocol.
Standard of Care (SOC)
IV infusion or oral tablets
Lenvatinib 20 mg
Participants with body weight (BW)\>60kg receive Lenvatinib 20mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
Lenvatinib
Oral capsules
Lenvatinib 24 mg
Participants with body weight (BW)\>60 kg receive Lenvatinib 24 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
Lenvatinib
Oral capsules
Lenvatinib 12 mg
Participants with body weight (BW)\>60 kg receive Lenvatinib 12 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
Lenvatinib
Oral capsules
Lenvatinib 8 mg
Participants with body weight (BW)\<60 kg receive Lenvatinib 8 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
Lenvatinib
Oral capsules
Lenvatinib 2mg
Participants with body weight (BW)\<60 kg receive Lenvatinib 2 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumab administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
Lenvatinib
Oral capsules
Olaparib 300mg
Participants receive Olaparib 300 mg orally twice daily (BID) until disease progression or toxicity prohibits its administration.
Olaparib
300mg or 250mg or 100mg oral tablers
Olaparib 250mg
Participants receive Olaparib 250 mg orally twice daily (BID) until disease progression or toxicity prohibits its administration.
Olaparib
300mg or 250mg or 100mg oral tablers
Olaparib 100mg
Participants receive Olaparib 100 mg orally twice daily (BID) until disease progression or toxicity prohibits its administration.
Olaparib
300mg or 250mg or 100mg oral tablers
MK-4280 800mg
Participants receive MK-4280 800mg as IV infusion every 3 weeks (Q3W) and may continue study therapy until study treatment completion or may transition to pembrolizumab to complete their treatment.
MK-4280
IV Infusion
MK-4280A
Participants receive MK-4280A (800mg favezelimab + 200mg pembrolizumab) as IV infusion every 3 weeks (Q3W) and may continue study therapy until study treatment completion or may transition to pembrolizumab to complete their treatment.
MK-4280A
800mg favezelimab + 200mg pembrolizumab IV Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
200 or 400 mg IV infusion
Standard of Care (SOC)
IV infusion or oral tablets
Lenvatinib
Oral capsules
Olaparib
300mg or 250mg or 100mg oral tablers
MK-4280
IV Infusion
MK-4280A
800mg favezelimab + 200mg pembrolizumab IV Infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently receiving pembrolizumab, pembrolizumab based combinations or lenvatinib from parent studies or in a follow-up phase.
Additional eligibility criteria for participants who enter Second Course Phase once they are enrolled on MK-3475-587:
* Has not received any anticancer systemic treatment since the last dose of pembrolizumab or a pembrolizumab-based combination in First Course Phase.
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Demonstrates adequate organ function.
* Have resolution of any toxic effect(s) of First Course Phase trial treatment with pembrolizumab or a pembrolizumab-based combination to Grade 1 or less (except alopecia) before trial treatment in Second Course Phase is started. If participant received major surgery or radiation therapy of \>30 Gray (Gy), they must have recovered from the toxicity and/or complications of the intervention.
* A female participant is eligible to enroll if she is not pregnant, not breastfeeding, and ≥1 of the following conditions applies: A woman of childbearing potential (WOCBP) who agrees to use contraception during the study treatment period and for ≥120 days (corresponding to time needed to eliminate any study combination treatment(s) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity.
Additional eligibility criteria for participants who enter dosing with Lenvatinib:
* Adequately controlled blood pressure (BP) to \<150/90 mmHg, with or without antihypertensive medications.
* For male agrees to be abstinent from penile-vaginal intercourse OR agrees to use a highly effective contraceptive method while receiving study drug and for 7 days after the last dose of lenvatinib.
* Is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (WOCBP), is a WOCBP and uses highly effective contraception (low user dependency method OR a user dependent hormonal method in combination with a barrier method) or is a WOCBP who is abstinent from heterosexual intercourse.
Exclusion Criteria
* Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.
* Has received a live vaccine within 30 days prior to the first dose of Second Course Phase trial treatment.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the Cycle 1 Day 1 of Second Course Phase.
* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with curative intent, melanoma (non-ulcerated, thin primary), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy.
* Has known active central nervous system metastases and/or carcinomatous meningitis.
* Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. Note: Participants that experienced pneumonitis during First Course that did not meet the criteria for permanent discontinuation are eligible.
* Non-small cell lung cancer (NSCLC) participants only: Has interstitial lung disease.
* Has an active infection requiring systemic therapy.
* Has a known history of human immunodeficiency virus (HIV) infection.
* Has a known history of or is positive for hepatitis B or hepatitis C. For parent studies where inclusion of participants with hepatitis was permitted, MK-3475-587 will follow the parent study eligibility criteria for hepatitis.
* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Second Course Phase eligibility Visit through 120 days after the last dose of study treatment.
* Has severe cardiovascular disease, i.e., arrhythmias, requiring chronic treatment, congestive heart failure (New York Heart Association Class III or IV) or symptomatic ischemic heart disease.
* Has hepatic decompensation (Child-Pugh score \>6 \[class B and C\]).
* Has uncontrolled thyroid dysfunction.
* Has uncontrolled diabetes mellitus.
* Has had an allogeneic tissue/solid organ transplant.
* Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
* Has had major surgery within 3 weeks prior to first dose of study intervention(s).
* Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.
* Has urine protein ≥1 g/24 hours.
* Has LVEF below the institutional (or local laboratory) normal range, as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).
* Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation.
* Prolongation of QT intervals corrected for heart rate using Fridericia's (cube root) correction (QTcF) interval to \>480 ms.
* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
* Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib.
* Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
* Has a history of any contraindication or has a severe hypersensitivity to any components of lenvatinib.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinica Viver ( Site 1021)
Santa Maria, Rio Grande do Sul, Brazil
CEPON ( Site 1012)
Florianópolis, Santa Catarina, Brazil
Arizona Cancer Center at UMC North ( Site 0018)
Tucson, Arizona, United States
Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054)
Bakersfield, California, United States
California Cancer Associates for Research & Excellence ( Site 0016)
Fresno, California, United States
Providence Medical Foundation ( Site 0087)
Fullerton, California, United States
The Angeles Clinic and Research Institute ( Site 0005)
Los Angeles, California, United States
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0009)
Los Angeles, California, United States
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0076)
Orange, California, United States
Stanford Cancer Center ( Site 0086)
Palo Alto, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0004)
San Francisco, California, United States
Providence Saint John's Health Center ( Site 0059)
Santa Monica, California, United States
University of Colorado Cancer Center ( Site 0021)
Aurora, Colorado, United States
Yale Cancer Center ( Site 0014)
New Haven, Connecticut, United States
Georgetown University Medical Center ( Site 0023)
Washington D.C., District of Columbia, United States
Holy Cross Hospital, Michael & Dianne Bienes Comp Cancer Ctr ( Site 0022)
Fort Lauderdale, Florida, United States
Baptist MD Anderson Cancer Center ( Site 0083)
Jacksonville, Florida, United States
Mount Sinai Medical Center Comprehensive Cancer Center ( Site 0031)
Miami Beach, Florida, United States
Moffitt Cancer Center ( Site 0011)
Tampa, Florida, United States
Emory School of Medicine ( Site 0013)
Atlanta, Georgia, United States
Augusta University ( Site 0077)
Augusta, Georgia, United States
Northwest Georgia Oncology Centers PC ( Site 0061)
Marietta, Georgia, United States
Kaiser Permanente Moanalua Medical Center ( Site 0063)
Honolulu, Hawaii, United States
The University of Chicago ( Site 0020)
Chicago, Illinois, United States
University of Iowa Hospital and Clinics ( Site 0026)
Iowa City, Iowa, United States
James Graham Brown Cancer Center ( Site 0058)
Louisville, Kentucky, United States
Mercy Health-Paducah Cancer Center ( Site 0084)
Paducah, Kentucky, United States
Women's Cancer Care ( Site 0088)
Covington, Louisiana, United States
MedStar Franklin Square Medical Center ( Site 0046)
Baltimore, Maryland, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0056)
Baltimore, Maryland, United States
Maryland Oncology Hematology (MOH) ( Site 8000)
Columbia, Maryland, United States
Massachusetts General Hospital ( Site 0041)
Boston, Massachusetts, United States
Dana-Farber Cancer Institute ( Site 0006)
Boston, Massachusetts, United States
Karmanos Cancer Institute ( Site 0047)
Detroit, Michigan, United States
Mayo Clinic in Rochester, Minnesota ( Site 0002)
Rochester, Minnesota, United States
Comprehensive Cancer Centers of Nevada ( Site 0043)
Las Vegas, Nevada, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0038)
Hackensack, New Jersey, United States
Cancer Institute of New Jersey ( Site 0025)
New Brunswick, New Jersey, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032)
New York, New York, United States
Memorial Sloan Kettering Cancer Center ( Site 0012)
New York, New York, United States
White Plains Hospital-Center for Cancer Care ( Site 0069)
White Plains, New York, United States
WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074)
Cary, North Carolina, United States
University of North Carolina at Chapel Hill ( Site 0040)
Chapel Hill, North Carolina, United States
Levine Cancer Institute ( Site 0034)
Charlotte, North Carolina, United States
Duke Cancer Center ( Site 0028)
Durham, North Carolina, United States
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0065)
Fargo, North Dakota, United States
University Hospitals ( Site 0044)
Cleveland, Ohio, United States
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0082)
Tulsa, Oklahoma, United States
Providence Portland Medical Center ( Site 0051)
Portland, Oregon, United States
St. Luke's University Health Network ( Site 0017)
Bethlehem, Pennsylvania, United States
University of Pennsylvania ( Site 0010)
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center ( Site 0042)
Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center ( Site 0008)
Pittsburgh, Pennsylvania, United States
Saint Francis Health System ( Site 0089)
Greenville, South Carolina, United States
Sanford Cancer Center ( Site 0066)
Sioux Falls, South Dakota, United States
West Cancer Center and Research Institute ( Site 0055)
Germantown, Tennessee, United States
Vanderbilt Health One Hundred Oaks Diagnostic ( Site 0060)
Nashville, Tennessee, United States
Vanderbilt Ingram Cancer Center ( Site 0015)
Nashville, Tennessee, United States
Texas Oncology - Central/South Texas ( Site 8001)
Austin, Texas, United States
Texas Oncology-Baylor Sammons Cancer Center ( Site 0062)
Dallas, Texas, United States
University of Texas MD Anderson Cancer Center ( Site 0007)
Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)
San Antonio, Texas, United States
University of Virginia Health System ( Site 0035)
Charlottesville, Virginia, United States
Bon Secours St. Francis Medical Center-Oncology Research ( Site 0075)
Midlothian, Virginia, United States
VCU Health Adult Outpatient Pavillion ( Site 0080)
Richmond, Virginia, United States
Blue Ridge Cancer Care ( Site 0067)
Roanoke, Virginia, United States
Fred Hutchinson Cancer Center ( Site 0024)
Seattle, Washington, United States
Centro de Oncología e Investigación de Buenos Aires ( Site 1357)
Berazategui, Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 1368)
Buenos Aires., Buenos Aires, Argentina
Fundacion Favaloro ( Site 1367)
CABA, Buenos Aires, Argentina
Derma Internacional SA ( Site 1372)
CABA, Buenos Aires, Argentina
Instituto Alexander Fleming ( Site 1364)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
IDIM - Instituto de Investigaciones Metabólicas ( Site 1362)
Ciudad de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 1363)
Mar del Plata, Buenos Aires, Argentina
Instituto Médico Río Cuarto ( Site 1375)
Río Cuarto, Córdoba Province, Argentina
Clinica Viedma ( Site 1353)
Viedma, Río Negro Province, Argentina
Fundacion Estudios Clinicos ( Site 1369)
Rosario, Santa Fe Province, Argentina
Sanatorio Parque ( Site 1355)
Rosario, Santa Fe Province, Argentina
Instituto de Oncologia de Rosario ( Site 1350)
Rosario, Santa Fe Province, Argentina
Hospital Provincial del Centenario ( Site 1359)
Rosario, Santa Fe Province, Argentina
Hospital Aleman-Oncology ( Site 1351)
Buenos Aires, , Argentina
Centro Medico Privado CEMAIC ( Site 1371)
Córdoba, , Argentina
Hospital Privado Universitario de Córdoba ( Site 1354)
Córdoba, , Argentina
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 1358)
La Rioja, , Argentina
Instituto San Marcos ( Site 1366)
San Juan, , Argentina
Centro Medico San Roque-Oncology ( Site 1352)
San Miguel de Tucumán, , Argentina
Centro Oncologico Norte. ( Site 1370)
Santiago del Estero, , Argentina
Chris OBrien Lifehouse ( Site 3003)
Camperdown, New South Wales, Australia
Royal Prince Alfred Hospital-A.W. Morrow Gastroenterology and Liver Centre ( Site 3016)
Camperdown, New South Wales, Australia
Liverpool Hospital-Medical Oncology ( Site 3021)
Liverpool, New South Wales, Australia
Macquarie University ( Site 3010)
Macquarie University, New South Wales, Australia
Mater Hospital Sydney ( Site 3007)
North Sydney, New South Wales, Australia
Orange Hospital-Clinical Trials Unit ( Site 3027)
Orange, New South Wales, Australia
Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3020)
Port Macquarie, New South Wales, Australia
Royal North Shore Hospital-Medical Oncology Clinical Trials ( Site 3025)
St Leonards, New South Wales, Australia
Calvary Mater Newcastle ( Site 3005)
Waratah, New South Wales, Australia
Westmead Hospital ( Site 3000)
Westmead, New South Wales, Australia
Melanoma Institute Australia ( Site 3001)
Wollstonecraft, New South Wales, Australia
Mater Misericordiae Limited-Medical Oncology ( Site 3019)
Brisbane, Queensland, Australia
Gallipoli Medical Research Ltd ( Site 3011)
Brisbane, Queensland, Australia
Royal Brisbane and Women's Hospital ( Site 3009)
Herston, Queensland, Australia
Tasman Oncology Research Pty Ltd ( Site 3012)
Southport, Queensland, Australia
The Townsville Hospital ( Site 3017)
Townsville, Queensland, Australia
Princess Alexandra Hospital ( Site 3002)
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital ( Site 3014)
Adelaide, South Australia, Australia
The Queen Elizabeth Hospital ( Site 3026)
Woodville, South Australia, Australia
Monash Health ( Site 3015)
Clayton, Victoria, Australia
Austin Health-Austin Hospital ( Site 3004)
Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3008)
Melbourne, Victoria, Australia
St Vincent's Hospital-Oncology Clinical Trials ( Site 3018)
Melbourne, Victoria, Australia
Western Health-Sunshine & Footscray Hospitals ( Site 3023)
St Albans, Victoria, Australia
Ballarat Oncology & Haematology Services ( Site 3022)
Wendouree, Victoria, Australia
Fiona Stanley Hospital ( Site 3029)
Murdock, Western Australia, Australia
Sir Charles Gairdner Hospital ( Site 3006)
Nedlands, Western Australia, Australia
St John of God Subiaco Hospital ( Site 3013)
Subiaco, Western Australia, Australia
Medical University of Graz ( Site 2952)
Graz, Styria, Austria
Medizinische Universitaet Innsbruck ( Site 2951)
Innsbruck, Tyrol, Austria
Kepler Universitätsklinikum ( Site 2955)
Linz, Upper Austria, Austria
Uniklinikum Salzburg ( Site 2956)
Salzburg, , Austria
Medizinische Universität Wien ( Site 2953)
Vienna, , Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2954)
Vienna, , Austria
AZ Sint-Maarten ( Site 2904)
Mechelen, Antwerpen, Belgium
Institut Jules Bordet ( Site 2903)
Anderlecht, Bruxelles-Capitale, Region de, Belgium
Cliniques Universitaires de Bruxelles - CUB - Hopital Erasme ( Site 2905)
Brussels, Bruxelles-Capitale, Region de, Belgium
UZ Brussel ( Site 2900)
Brussels, Bruxelles-Capitale, Region de, Belgium
Cliniques universitaires Saint-Luc-Medical Oncology ( Site 2911)
Brussels, Bruxelles-Capitale, Region de, Belgium
AZ Maria Middelares ( Site 2908)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 2901)
Leuven, Vlaams-Brabant, Belgium
UZ Leuven - Campus Gasthuisberg ( Site 2906)
Leuven, Vlaams-Brabant, Belgium
UZ Leuven Gasthuisberg, Gynaecologie-Verloskunde ( Site 2907)
Leuven, Vlaams-Brabant, Belgium
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi ( Site 2909)
Namur, , Belgium
Hospital São Carlos-Oncocentro Ce ( Site 1029)
Fortaleza, Ceará, Brazil
CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA-Pesquisa Clínica ( Site 1024)
Fortaleza, Ceará, Brazil
Centro de Pesquisa Clínica do Instituto do Câncer do Ceará ( Site 1016)
Fortaleza, Ceará, Brazil
Hospital Erasto Gaertner ( Site 1036)
Curitiba, Paraná, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 1008)
Ijuí, Rio Grande do Sul, Brazil
Hospital de Clínicas de Passo Fundo ( Site 1025)
Passo Fundo, Rio Grande do Sul, Brazil
Lacks - Oncologia E Hematologia ( Site 1026)
Pelotas, Rio Grande do Sul, Brazil
Hospital de Clinicas de Porto Alegre ( Site 1000)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital São Lucas da PUCRS-Centro de Pesquisa em Oncologia ( Site 1006)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceição ( Site 1011)
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1010)
Barretos, São Paulo, Brazil
Hospital Amaral Carvalho ( Site 1023)
Jaú, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1003)
São José do Rio Preto, São Paulo, Brazil
Clínica de Pesquisa e Centro de Estudos em Ginecologia Oncológica e Mamária LTDA ( Site 1017)
São Paulo, São Paulo, Brazil
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 1020)
Rio de Janeiro, , Brazil
Instituto de de Educação, pesquisa e Gestão em Saúde ( Site 1014)
Rio de Janeiro, , Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 1001)
São Paulo, , Brazil
BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 1030)
São Paulo, , Brazil
A. C. Camargo Cancer Center ( Site 1002)
São Paulo, , Brazil
Arthur J.E. Child Comprehensive Cancer Centre ( Site 2815)
Calgary, Alberta, Canada
Cross Cancer Institute ( Site 2804)
Edmonton, Alberta, Canada
CancerCare Manitoba ( Site 2814)
Winnipeg, Manitoba, Canada
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2801)
Hamilton, Ontario, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2808)
Kingston, Ontario, Canada
London Regional Cancer Program - LHSC ( Site 2806)
London, Ontario, Canada
The Ottawa Hospital - General Campus ( Site 2813)
Ottawa, Ontario, Canada
Sunnybrook Research Institute ( Site 2802)
Toronto, Ontario, Canada
Mount Sinai Hospital ( Site 2811)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 2803)
Toronto, Ontario, Canada
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre-Oncology ( Site 2809)
Greenfield Park, Quebec, Canada
Centre Intégré de Santé et de Services Sociaux (CISSS) de La-Centre intégré de cancérologie de Lava ( Site 2810)
Laval, Quebec, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 2807)
Montreal, Quebec, Canada
Jewish General Hospital ( Site 2800)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 2818)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 2805)
Québec, Quebec, Canada
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 2812)
Sherbrooke, Quebec, Canada
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 2816)
Trois-Rivières, Quebec, Canada
Orlandi Oncologia-Oncology ( Site 2752)
Santiago, Region M. de Santiago, Chile
Fundacion Arturo Lopez Perez FALP ( Site 2750)
Santiago, Region M. de Santiago, Chile
Oncovida ( Site 2759)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 2751)
Santiago, Region M. de Santiago, Chile
Instituto Nacional del Cancer-CR Investigación ( Site 2753)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 2756)
Santiago, Region M. de Santiago, Chile
James Lind Centro de Investigacion del Cancer ( Site 2757)
Temuco, Región de la Araucanía, Chile
ONCOCENTRO APYS-ACEREY ( Site 2758)
Viña del Mar, Región de Valparaíso, Chile
Centro de Investigaciones ( Site 2755)
Viña del Mar, Región de Valparaíso, Chile
Anhui Provincial Hospital-Cancer Chemotherapy Department ( Site 3480)
Hefei, Anhui, China
Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 3487)
Hefei, Anhui, China
Beijing Cancer Hospital ( Site 3451)
Beijing, Beijing Municipality, China
The Fifth Medical Center Of The Chinese PLA General Hospital (South) ( Site 3465)
Beijing, Beijing Municipality, China
Beijing Cancer Hospital ( Site 3499)
Beijing, Beijing Municipality, China
Beijing Cancer Hospital ( Site 3500)
Beijing, Beijing Municipality, China
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 3454)
Beijing, Beijing Municipality, China
Chinese Academy of medical science, Peking Union Medical College Hospital(Dongdan) ( Site 3466)
Beijing, Beijing Municipality, China
Army Medical Center of People's Liberation Army-Oncology Department ( Site 3477)
Chongqing, Chongqing Municipality, China
Fujian Provincial Cancer Hospital ( Site 3461)
Fuzhou, Fujian, China
Southern medical university Nangfang Hospital ( Site 3490)
Guanghzou, Guangdong, China
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 3491)
Guangzhou, Guangdong, China
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal Medicine ( Site 3452)
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center-melanoma ( Site 3482)
Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital-Cancer Center ( Site 3462)
Guangzhou, Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University-pneumology department ( Site 3459)
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University-thoracic surgery department ( Site 3460)
Guangzhou, Guangdong, China
The Affiliated Cancer Hospital of Guizhou Medical University ( Site 3498)
Guiyang, Guizhou, China
Harbin Medical University Cancer Hospital ( Site 3506)
Harbin, Heilongjiang, China
Harbin Medical University Cancer Hospital-Harbin Medical University Cancer Hospital ( Site 3475)
Harbin, Heilongjiang, China
Henan Cancer Hospital ( Site 3488)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical,Science & Technology-oncology ( Site 3476)
Wuhan, Hubei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3492)
Wuhan, Hubei, China
Xiangya Hospital Central South University ( Site 3508)
Changsha, Hunan, China
Xiangya Hospital Central South University-Gynecology ( Site 3497)
Changsha, Hunan, China
Xiangya Hospital Central South University-Respiratory ( Site 3479)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 3485)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 3501)
Changsha, Hunan, China
Jiangsu Cancer Hospital-Medical Oncotherapy ( Site 3469)
Nanjing, Jiangsu, China
Yancheng First People s Hospital ( Site 3504)
Yancheng, Jiangsu, China
Northern Jiangsu People's Hospital-General Surgery Department ( Site 3474)
Yangzhou, Jiangsu, China
The First Hospital of Jilin University-Oncology ( Site 3464)
Changchun, Jilin, China
Jilin Province Tumor Hospital ( Site 3484)
Changchun, Jilin, China
Tangdu Hospital of Fourth Military Medical University of Chi-department of radiotherapy ( Site 3455)
Xi'an, Shaanxi, China
Fudan University Shanghai Cancer Center ( Site 3467)
Shanghai, Shanghai Municipality, China
Zhongshan Hospital of Fudan University ( Site 3503)
Shanghai, Shanghai Municipality, China
Obstetrics & Gynecology Hospital of Fudan University ( Site 3494)
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital ( Site 3470)
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Xi an Jiaotong University ( Site 3489)
XiAn, Shanxi, China
West China Hospital Sichuan University-respiratory ( Site 3473)
Chengdu, Sichuan, China
Sichuan Cancer hospital. ( Site 3515)
Chengdu, Sichuan, China
The Second People's Hospital of Yibin ( Site 3516)
Yibin, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital ( Site 3456)
Tianjin, Tianjin Municipality, China
Xinjiang Medical University Cancer Hospital - Urumqi-galactophore department ( Site 3486)
Ürümqi, Xinjiang, China
The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 3502)
Ürümqi, Xinjiang, China
Women s Hospital School of Medicine Zhejiang University ( Site 3493)
Hangzhou, Zhejiang, China
Hangzhou Cancer Hospital-Medical Oncology ( Site 3468)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 3495)
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital ( Site 3505)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 3481)
Hangzhou, Zhejiang, China
Instituto de Cancerología-Oncology ( Site 2702)
Medellín, Antioquia, Colombia
Fundacion Colombiana de Cancerología Clinica Vida ( Site 2707)
Medellín, Antioquia, Colombia
Clinica de la Costa S.A.S. ( Site 2705)
Barranquilla, Atlántico, Colombia
Administradora Country S.A. ( Site 2701)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 2704)
Valledupar, Cesar Department, Colombia
Instituto Nacional De Cancerologia-Oncología Clínica ( Site 2706)
Bogota, Cundinamarca, Colombia
IMAT S.A.S ( Site 2703)
Montería, Departamento de Córdoba, Colombia
Fundación Valle del Lili ( Site 2700)
Cali, Valle del Cauca Department, Colombia
Clínica Imbanaco S.A.S ( Site 2708)
Cali, Valle del Cauca Department, Colombia
CIMCA ( Site 3900)
San José, , Costa Rica
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0703)
Brno, Brno-mesto, Czechia
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0704)
Olomouc, Olomoucký kraj, Czechia
Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 0702)
Prague, Praha 4, Czechia
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0705)
Prague, Praha 5, Czechia
Fakultni nemocnice Olomouc ( Site 0701)
Olomouc, , Czechia
Fakultni nemocnice v Motole ( Site 0700)
Prague, , Czechia
Odense Universitetshospital ( Site 0650)
Odense, Region Syddanmark, Denmark
Vejle Sygehus ( Site 0653)
Vejle, Region Syddanmark, Denmark
Tartu University Hospital-Radiotherapy and oncology ( Site 3800)
Tartu, Tartu, Estonia
Tampere University Hospital [Tampere Finland] ( Site 0600)
Tampere, Pirkanmaa, Finland
Turku University Hospital ( Site 0601)
Turku, Southwest Finland, Finland
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 2539)
Nice, Alpes-Maritimes, France
Nouvel Hôpital Civil (NHC) ( Site 2529)
Strasbourg, Alsace, France
CHU Bordeaux Haut-Leveque ( Site 2534)
Pessac, Aquitaine, France
CH Lyon Sud Hospices Civils de Lyon ( Site 2521)
Pierre-Bénite, Auvergne-Rhône-Alpes, France
Centre Hopitalar Leon-Berard ( Site 2519)
Lyon, Auvergne, France
Hopital Nord ( Site 2516)
Marseille, Bouches-du-Rhone, France
Hôpital Privé Clairval ( Site 2549)
Marseille, Bouches-du-Rhone, France
CHU La Timone ( Site 2508)
Marseille, Bouches-du-Rhone, France
Centre Georges François Leclerc-Centre de recherche clinique ( Site 2536)
Dijon, Cote-d Or, France
CHU-Jean Minjoz ( Site 2550)
Besançon, Doubs, France
CHU Jean Minjoz ( Site 2520)
Besançon, Doubs, France
CHRU Brest - Hopital Cavale Blanche ( Site 2504)
Brest, Finistere, France
Institut Bergonie ( Site 2502)
Bordeaux, Gironde, France
CHU Toulouse - Hopital Rangueil ( Site 2518)
Toulouse, Haute-Garonne, France
CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 2526)
Toulouse, Haute-Garonne, France
Centre Hospitalier Annecy Genevois ( Site 2554)
Epagny Metz Tessy, Haute-Savoie, France
Centre Oscar Lambret ( Site 2551)
Lille, Hauts-de-France, France
Ambroise Pare Hopital ( Site 2503)
Boulogne, Hauts-de-Seine, France
Hôpital Foch ( Site 2543)
Suresnes, Hauts-de-Seine, France
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 2525)
Rennes, Ille-et-Vilaine, France
Hopital Trousseau ( Site 2512)
Chambray-lès-Tours, Indre-et-Loire, France
C.H.U. de Tours - Hopital Bretonneau ( Site 2515)
Tours, Indre-et-Loire, France
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes-lung oncology ( Site 2546)
Saint-Herblain, Loire-Atlantique, France
Institut de Cancérologie de l'Ouest-Oncologie Médicale ( Site 2522)
Saint-Herblain, Loire-Atlantique, France
Institut de Cancérologie de Lorraine Alexis Vautrin ( Site 2532)
Vandœuvre-lès-Nancy, Lorraine, France
CHRU Lille Hospital Claude Huriez ( Site 2506)
Lille, Nord, France
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 2542)
Clermont-Ferrand, Puy-de-Dome, France
C.H.U. Pontchaillou ( Site 2511)
Pierre-Bénite, Rhone, France
Centre Hospitalier du Mans-Pneumologie ( Site 2527)
Le Mans, Sarthe, France
Centre Henri Becquerel ( Site 2547)
Rouen, Seine-Maritime, France
Hôpital Avicenne-Dermatologie ( Site 2538)
Bobigny, Seine-Saint-Denis, France
Clinique de L'Europe ( Site 2548)
Amiens, Somme, France
Centre Hopitalier Intercommunal Creteil ( Site 2514)
Créteil, Val-de-Marne, France
Hôpital Universitaire Paul Brousse ( Site 2541)
Villejuif, Val-de-Marne, France
Centre Hospitalier Universitaire de Poitiers-Dermatologie ( Site 2544)
Poitiers, Vienne, France
Hopital Cochin ( Site 2509)
Paris, , France
Hopital Saint Louis ( Site 2510)
Paris, , France
CHU Hopital Saint Antoine ( Site 2517)
Paris, , France
Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 2545)
Paris, , France
Hôpital Tenon ( Site 2530)
Paris, , France
Hôpital Beaujon ( Site 2524)
Clichy, Île-de-France Region, France
Groupe hospitalier Paris saint Joseph-Service de Pneumologie-Allergologie -Oncologie Thoracique ( Site 2533)
Paris, Île-de-France Region, France
Institut Gustave Roussy ( Site 2513)
Villejuif, Île-de-France Region, France
Universitaetsklinikum Tuebingen ( Site 2405)
Tübingen, Baden-Wurttemberg, Germany
Universitätsklinikum Erlangen ( Site 2408)
Erlangen, Bavaria, Germany
Universitaetsklinik Muenchen ( Site 2406)
Munich, Bavaria, Germany
Krankenhaus Nordwest ( Site 2409)
Frankfurt am Main, Hesse, Germany
Elbe Klinikum Buxtehude ( Site 2400)
Buxtehude, Lower Saxony, Germany
Medizinische Hochschule Hannover ( Site 2402)
Hanover, Lower Saxony, Germany
Universitaetsklinikum Essen ( Site 2404)
Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum des Saarlandes-Klinik für Innere Medizin V-Pneumologie, Allergologie, Beatmun ( Site 2411)
Homburg, Saarland, Germany
Universitatsklinikum Carl Gustav Carus ( Site 2407)
Dresden, Saxony, Germany
LungenClinic Grosshansdorf GmbH ( Site 2412)
Großhansdorf, Schleswig-Holstein, Germany
SRH Wald-Klinikum Gera GmbH ( Site 2403)
Gera, Thuringia, Germany
Helios Klinikum Emil von Behring Berlin-Zehlendorf-Lungenklinik Heckeshorn ( Site 2418)
Berlin, , Germany
Facharztzentrum Eppendorf ( Site 2415)
Hamburg, , Germany
General Hospital of Athens "Laiko"-Hematology Department ( Site 1851)
Athens, Attica, Greece
Sotiria Regional Chest Diseases Hospital of Athens ( Site 1850)
Athens, Attica, Greece
European Interbalkan Medical Center ( Site 1855)
Thessaloniki, , Greece
MEDI-K ( Site 3403)
Guatemala City, , Guatemala
Oncomedica ( Site 3401)
Guatemala City, , Guatemala
Grupo Medico Angeles ( Site 3402)
Guatemala City, , Guatemala
Queen Mary Hospital ( Site 1902)
Hksar, , Hong Kong
Queen Mary Hospital-Department of Medicine (Respiratory) ( Site 1900)
Hksar, , Hong Kong
Princess Margaret Hospital ( Site 1903)
Hong Kong, , Hong Kong
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház-Megyei Onkológiai Centrum ( Site 1405)
Gyula, Bekes County, Hungary
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház ( Site 1409)
Miskolc, Borsod-Abauj Zemplen county, Hungary
Fejér Megyei Szent György Egyetemi Oktató Kórház-l.Pulmonologia ( Site 1407)
Székesfehérvár, Fejér, Hungary
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 1401)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1411)
Budapest, Pest County, Hungary
Markusovszky Egyetemi Oktatokorhaz-Onkológiai Osztály ( Site 1410)
Szombathely, Vas County, Hungary
Farkasgyepui Tudogyogyintezet-Pulmonologia ( Site 1414)
Farkasgyepű, Veszprém megye, Hungary
Semmelweis University-Belgyógyászati és Hematológiai Klinika ( Site 1406)
Budapest, , Hungary
Orszagos Koranyi Pulmonologiai Intezet ( Site 1403)
Budapest, , Hungary
Uzsoki Utcai Kórház-Onkoradiológiai Osztály ( Site 1413)
Budapest, , Hungary
Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 1415)
Debrecen, , Hungary
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 1412)
Debrecen, , Hungary
Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1402)
Kaposvár, , Hungary
Zala Megyei Szent Rafael Korhaz ( Site 1400)
Zalaegerszeg, , Hungary
Mater Misercordiae University Hospital ( Site 1800)
Dublin, Leinster, Ireland
Tallaght University Hospital ( Site 1803)
Dublin, , Ireland
St. James s Hospital ( Site 1801)
Dublin, , Ireland
Rambam Health Care Campus-Oncology Division ( Site 2053)
Haifa, , Israel
Bnai Zion Medical Center ( Site 2060)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 2068)
Jerusalem, , Israel
Hadassah Ein Kerem Medical Center ( Site 2051)
Jerusalem, , Israel
Rabin Medical Center ( Site 2059)
Petah Tikva, , Israel
Chaim Sheba Medical Center. ( Site 2052)
Ramat Gan, , Israel
Chaim Sheba Medical Center ( Site 2055)
Ramat Gan, , Israel
Sheba Medical Center ( Site 2062)
Ramat Gan, , Israel
Sheba Medical Center ( Site 2065)
Ramat Gan, , Israel
ZIV Medical Center-Hematology Institute ( Site 2061)
Safed, , Israel
Sourasky Medical Center ( Site 2054)
Tel Aviv, , Israel
Shamir Medical Center Assaf Harofeh ( Site 2058)
Ẕerifin, , Israel
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1978)
Bologna, Emilia-Romagna, Italy
Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 1963)
Rome, Lazio, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1975)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1977)
Milan, Lombardy, Italy
Azienda Ospedaliera San Gerardo ( Site 1980)
Monza, Lombardy, Italy
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1968)
Rozzano, Milano, Italy
IRCCS CRO Aviano, Hematology/Oncology ( Site 1957)
Aviano, Pordenone, Italy
Ospedale Cannizzaro ( Site 1981)
Catania, Sicily, Italy
Istituto di Candiolo - IRCCS ( Site 1960)
Candiolo, Torino, Italy
Ospedale San Luigi Gonzaga ( Site 1956)
Orbassano, Torino, Italy
AO Santa Maria della Misericordia-Oncology Department ( Site 1971)
Perugia, Umbria, Italy
Istituto Oncologico Veneto IRCCS ( Site 1976)
Padua, Veneto, Italy
Humanitas Gavazzeni ( Site 1954)
Bergamo, , Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII-UOC Oncologia ( Site 1967)
Bergamo, , Italy
Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 1972)
Brescia, , Italy
IRCCS A.O.U. San Martino - IST ( Site 1961)
Genova, , Italy
Ospedale San Raffaele. ( Site 1979)
Milan, , Italy
Istituto Europeo di Oncologia ( Site 1952)
Milan, , Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1955)
Napoli, , Italy
Azienda Ospedaliero Universitaria di Parma-UO Oncologia Medica ( Site 1964)
Parma, , Italy
Fondazione IRCCS Policlinico San Matteo ( Site 1982)
Pavia, , Italy
Azienda Ospedaliera San Camillo Forlanini ( Site 1958)
Roma, , Italy
Policlinico Universitario Agostino Gemelli ( Site 1965)
Roma, , Italy
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 1969)
Siena, , Italy
Azienda Ospedaliera Santa Maria ( Site 1962)
Terni, , Italy
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ( Site 1974)
Torino, , Italy
National Hospital Organization Nagoya Medical Center ( Site 3109)
Nagoya, Aichi-ken, Japan
Aichi Cancer Center ( Site 3101)
Nagoya, Aichi-ken, Japan
Nagoya University Hospital ( Site 3151)
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 3121)
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center ( Site 3116)
Matsuyama, Ehime, Japan
Ehime University Hospital ( Site 3158)
Tōon, Ehime, Japan
Kurume University Hospital ( Site 3105)
Kurume, Fukuoka, Japan
National Hospital Organization Hokkaido Cancer Center ( Site 3160)
Sapporo, Hokkaido, Japan
Sapporo Kosei General Hospital ( Site 3172)
Sapporo, Hokkaido, Japan
Sapporo Medical University Hospital ( Site 3113)
Sapporo, Hokkaido, Japan
Hokkaido University Hospital ( Site 3165)
Sapporo, Hokkaido, Japan
Hyogo Cancer Center ( Site 3131)
Akashi, Hyōgo, Japan
National Hospital Organization Himeji Medical Center ( Site 3111)
Himeji, Hyōgo, Japan
Kobe City Medical Center General Hospital ( Site 3144)
Kobe, Hyōgo, Japan
Hyogo Medical University Hospital ( Site 3100)
Nishinomiya, Hyōgo, Japan
Ibaraki Prefectural Central Hospital ( Site 3180)
Kasama, Ibaraki, Japan
University of Tsukuba Hospital ( Site 3176)
Tsukuba, Ibaraki, Japan
Kanazawa University Hospital ( Site 3140)
Kanazawa, Ishikawa-ken, Japan
Iwate Medical University Hospital ( Site 3157)
Shiwa-gun, Iwate, Japan
Kagawa University Hospital ( Site 3171)
Kita, Kagawa-ken, Japan
Nippon Medical School Musashi Kosugi Hospital ( Site 3178)
Kawasaki, Kanagawa, Japan
St. Marianna University Hospital ( Site 3182)
Kawasaki, Kanagawa, Japan
Kitasato University Hospital ( Site 3142)
Sagamihara, Kanagawa, Japan
Yokohama City University Hospital ( Site 3163)
Yokohama, Kanagawa, Japan
Kanagawa Cancer Center ( Site 3137)
Yokohama, Kanagawa, Japan
Yokosuka Kyosai Hospital ( Site 3150)
Yokosuka, Kanagawa, Japan
Miyagi Cancer Center ( Site 3122)
Natori-shi, Miyagi, Japan
Tohoku University Hospital ( Site 3175)
Sendai, Miyagi, Japan
Sendai Kousei Hospital ( Site 3115)
Sendai, Miyagi, Japan
Nara Medical University Hospital ( Site 3110)
Kashihara, Nara, Japan
Niigata Cancer Center Hospital ( Site 3173)
Niigata, Niigata, Japan
Kurashiki Central Hospital ( Site 3132)
Kurashiki, Okayama-ken, Japan
University of the Ryukyus Hospital ( Site 3155)
Ginowan, Okinawa, Japan
Osaka International Cancer Institute ( Site 3129)
Chuo-ku, Osaka, Japan
Osaka Habikino Medical Center ( Site 3138)
Habikino, Osaka, Japan
Kansai Medical University Hospital ( Site 3126)
Hirakata, Osaka, Japan
Osaka Rosai Hospital ( Site 3148)
Sakai, Osaka, Japan
Kindai University Hospital ( Site 3102)
Sayama, Osaka, Japan
Kindai University Hospital ( Site 3135)
Sayama, Osaka, Japan
Kindai University Hospital ( Site 3166)
Sayama, Osaka, Japan
The University of Osaka Hospital ( Site 3168)
Suita, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital ( Site 3167)
Takatsuki, Osaka, Japan
Saitama Medical University International Medical Center ( Site 3118)
Hidaka, Saitama, Japan
Saitama Prefectural Cancer Center ( Site 3112)
Kitaadachi-gun, Saitama, Japan
Dokkyo Medical University Saitama Medical Center ( Site 3152)
Koshigaya, Saitama, Japan
National Defense Medical College Hospital ( Site 3177)
Tokorozawa, Saitama, Japan
Shizuoka Cancer Center ( Site 3128)
Nakatogari, Shizuoka, Japan
Jichi Medical University Hospital ( Site 3141)
Shimotsuke, Tochigi, Japan
Institute of Science Tokyo Hospital ( Site 3149)
Bunkyō, Tokyo, Japan
Cancer Institute Hospital of JFCR ( Site 3146)
Koto, Tokyo, Japan
Cancer Institute Hospital of JFCR ( Site 3164)
Koto, Tokyo, Japan
Toranomon Hospital ( Site 3134)
Minato-ku, Tokyo, Japan
Toranomon Hospital ( Site 3153)
Minato-ku, Tokyo, Japan
Kyorin University Hospital ( Site 3103)
Mitaka, Tokyo, Japan
Kyorin University Hospital ( Site 3147)
Mitaka-shi, Tokyo, Japan
Tokyo Medical University Hospital ( Site 3170)
Shinjuku-ku, Tokyo, Japan
National Hospital Organization Yamaguchi Ube Medical Center ( Site 3123)
Ube, Yamaguchi, Japan
Yamaguchi University Hospital ( Site 3114)
Ube, Yamaguchi, Japan
Chiba Cancer Center ( Site 3117)
Chiba, , Japan
National Hospital Organization Kyushu Medical Center ( Site 3136)
Fukuoka, , Japan
National Hospital Organization Kyushu Cancer Center ( Site 3169)
Fukuoka, , Japan
Kyushu University Hospital ( Site 3143)
Fukuoka, , Japan
Kyushu University Hospital ( Site 3185)
Fukuoka, , Japan
Gifu University Hospital ( Site 3161)
Gifu, , Japan
Hiroshima City Hiroshima Citizens Hospital ( Site 3119)
Hiroshima, , Japan
Hiroshima University Hospital ( Site 3154)
Hiroshima, , Japan
Kochi Health Sciences Center ( Site 3145)
Kochi, , Japan
Kumamoto University Hospital ( Site 3179)
Kumamoto, , Japan
Kyoto University Hospital ( Site 3181)
Kyoto, , Japan
Niigata University Medical & Dental Hospital ( Site 3174)
Niigata, , Japan
Okayama University Hospital ( Site 3107)
Okayama, , Japan
Osaka City General Hospital ( Site 3125)
Osaka, , Japan
National Hospital Organization Osaka National Hospital ( Site 3162)
Osaka, , Japan
Osaka General Medical Center ( Site 3184)
Osaka, , Japan
National Cancer Center Hospital ( Site 3130)
Tokyo, , Japan
St.Luke's International Hospital ( Site 3120)
Tokyo, , Japan
The Jikei University Hospital ( Site 3156)
Tokyo, , Japan
Nippon Medical School Hospital ( Site 3139)
Tokyo, , Japan
Tokyo Metropolitan Komagome Hospital ( Site 3133)
Tokyo, , Japan
Cancer Institute Hospital of JFCR ( Site 3108)
Tokyo, , Japan
Keio University Hospital ( Site 3127)
Tokyo, , Japan
Teikyo University Hospital ( Site 3104)
Tokyo, , Japan
Toyama Prefectural Central Hospital ( Site 3183)
Toyama, , Japan
Wakayama Medical University Hospital ( Site 3124)
Wakayama, , Japan
Liepjas reionl slimnca ( Site 3851)
Liepāja, , Latvia
RIGA EAST UNIVERSITY HOSPITAL ,Oncology Centre of Latvia-Out-patient and Day patient facility of Ch ( Site 3850)
Riga, , Latvia
Klaipeda University Hospital-Oncology chemotherapy ( Site 3302)
Klaipėda, Klaipedos Miestas, Lithuania
Vilniaus Universiteto Ligonine Santaros Klinikos ( Site 3300)
Vilnius, , Lithuania
Vilnius University Hospital Santaros Clinics Affiliate - National Cancer Center ( Site 3301)
Vilnius, , Lithuania
Hospital Tengku Ampuan Afzan ( Site 0627)
Kuantan, Pahang, Malaysia
Gleneagles Penang ( Site 0625)
George Town, Pulau Pinang, Malaysia
Pantai Hospital Kuala Lumpur ( Site 0628)
Kuala Lumpur, , Malaysia
University Malaya Medical Centre ( Site 0626)
Kuala Lumpur, , Malaysia
Investigación Oncofarmacéutica-Investigación clínica ( Site 1114)
La Paz, Baja California Sur, Mexico
INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1102)
Mexico City, Mexico City, Mexico
Avix Investigación Clinica, S.C.-Oncology ( Site 1104)
Monterrey, Nuevo León, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 1113)
Monterrey, Nuevo León, Mexico
Centro de Urologa Avanzada del Noreste ( Site 1110)
San Pedro Garza García, Nuevo León, Mexico
Oaxaca Site Management Organization ( Site 1106)
Oaxaca City, Oaxaca, Mexico
Medical Care and Research SA de CV ( Site 1103)
Mérida, Yucatán, Mexico
Oncare Viaducto Napoles ( Site 1107)
Mexico City, , Mexico
Radboud University Medical Center ( Site 1554)
Nijmegen, Gelderland, Netherlands
Antoni van Leeuwenhoek Ziekenhuis ( Site 1551)
Amsterdam, North Holland, Netherlands
Amsterdam UMC, locatie VUmc ( Site 1555)
Amsterdam, North Holland, Netherlands
Erasmus MC ( Site 1553)
Rotterdam, South Holland, Netherlands
Universitair Medisch Centrum Groningen ( Site 1550)
Groningen, , Netherlands
Canterbury Regional Cancer & Blood Service ( Site 1500)
Christchurch, Canterbury, New Zealand
Waikato Hospital ( Site 1502)
Hamilton, Waikato Region, New Zealand
Auckland City Hospital ( Site 1503)
Auckland, , New Zealand
Capital & Coast District Health Board - Wellington Hospital ( Site 1501)
Wellington, , New Zealand
Helse Bergen Haukeland universitetssykehus ( Site 1451)
Bergen, Vestfold, Norway
Oslo Universitetssykehus Radiumhospitalet ( Site 1450)
Oslo, , Norway
Oslo universitetssykehus, Radiumhospitalet ( Site 1452)
Oslo, , Norway
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 0678)
Lima, , Peru
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 0681)
Lima, , Peru
Hospital Cayetano Heredia-Oncology ( Site 0675)
Lima, , Peru
Makati Medical Center ( Site 1702)
Makati City, National Capital Region, Philippines
Lung Center of the Philippines ( Site 1705)
Quezon City, National Capital Region, Philippines
St. Luke s Medical Center ( Site 1700)
Quezon City, National Capital Region, Philippines
Przychodnia Lekarska KOMED ( Site 1603)
Konin, Greater Poland Voivodeship, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 1607)
Poznan, Greater Poland Voivodeship, Poland
Med-Polonia Sp. z o. o. ( Site 1605)
Poznan, Greater Poland Voivodeship, Poland
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu Medycznego im. K. Marcinkowskiego w Pozna ( Site 1601)
Poznan, Greater Poland Voivodeship, Poland
Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 1619)
Poznan, Greater Poland Voivodeship, Poland
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1612)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 1608)
Krakow, Lesser Poland Voivodeship, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 1618)
Krakow, Lesser Poland Voivodeship, Poland
Luxmed Onkologia sp. z o. o. ( Site 1621)
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1604)
Warsaw, Masovian Voivodeship, Poland
Wojskowy Instytut Medyczny-Klinika Onkologii ( Site 1606)
Warsaw, Masovian Voivodeship, Poland
Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Kosza-Klinika Onkologii z Odcinkiem Dziennym ( Site 1616)
Opole, Opole Voivodeship, Poland
Bialostockie Centrum Onkologii ( Site 1610)
Bialystok, Podlaskie Voivodeship, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1620)
Gliwice, Silesian Voivodeship, Poland
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 1614)
Koszalin, West Pomeranian Voivodeship, Poland
Powiatowe Centrum Zdrowia w Brzezinach Sp. z o. o. Oddział Dziennej Chemioterapii ( Site 1611)
Brzeziny, Łódź Voivodeship, Poland
Instytut Centrum Zdrowia Matki Polki-Klinika Onkologii ( Site 1609)
Lodz, Łódź Voivodeship, Poland
Champalimaud Foundation ( Site 1751)
Lisbon, Lisbon District, Portugal
Unidade Local de Saude de Santa Maria - Hospital Pulido Valente ( Site 1750)
Lisbon, , Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE-Oncologia Médica ( Site 1753)
Porto, , Portugal
Centro Hospitalar de Sao Joao - Hospital de Sao Joao ( Site 1752)
Porto, , Portugal
Ad-Vance Medical Research-Research ( Site 1151)
Ponce, , Puerto Rico
FDI Clinical Research ( Site 1152)
San Juan, , Puerto Rico
UPR Comprehensive Cancer Center ( Site 1150)
San Juan, , Puerto Rico
Centrul de Oncologie "Sfântul Nectarie" ( Site 3552)
Craiova, Dolj, Romania
Institutul Oncologic "Prof. Dr. Ioan Chiricuta" ( Site 3551)
Cluj-Napoca, , Romania
Spitalul Județean Sfântul Ioan cel Nou Suceava-Oncology ( Site 3550)
Suceava, , Romania
Altai Regional Clinical Oncology Center ( Site 1229)
Barnaul, Altayskiy Kray, Russia
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1204)
Ufa, Baskortostan, Respublika, Russia
Bashkir State Medical University ( Site 1221)
Ufa, Baskortostan, Respublika, Russia
Belgorod Oncology Dispensary ( Site 1213)
Belgorod, Belgorod Oblast, Russia
Regional Budgetary Healthcare Institution 'Ivanovo Regional Oncology Dispensary'-Urology ( Site 1219)
Ivanovo, Ivanovo Oblast, Russia
Oncological Dispensary #2 of Ministry of Health of Krasnodar region ( Site 1244)
Sochi, Krasnodarskiy Kray, Russia
GBUZ LOKB ( Site 1218)
Saint-Petersburg, Leningradskaya Oblast', Russia
GBUZ LOKB-Oncology department #1 ( Site 1222)
Saint-Petersburg, Leningradskaya Oblast', Russia
Ogarev Mordovia State University ( Site 1206)
Saransk, Mordoviya, Respublika, Russia
The National Medico-Surgical Center N.I. Pirogov ( Site 1225)
Moscow, Moscow, Russia
N.N. Blokhin NMRCO ( Site 1209)
Moscow, Moscow, Russia
Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1201)
Moscow, Moscow, Russia
FSBI-FRCC of Special Types Med. Care and Technologies FMBA of Russia ( Site 1234)
Moscow, Moscow, Russia
Russian Scientific Center of Roentgenoradiology ( Site 1215)
Moscow, Moscow, Russia
First Moscow State Medical University n.a. I.M.Sechenov ( Site 1245)
Moscow, Moscow, Russia
P. A. Hertsen Moscow Oncology Research Center ( Site 1214)
Moscow, Moscow, Russia
FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 1208)
Moscow, Moscow, Russia
Volga District Medical Center Federal Medical and Biological Agency ( Site 1242)
Nizhny Novgorod, Nizhny Novgorod Oblast, Russia
Russian Scientific Research Institute of Hematology and Blood Transfusion-Hematology ( Site 1224)
Saint Petersburg, Sankt-Peterburg, Russia
St. Petersburg Clinical Hospital of Russian Academy Of Sciences ( Site 1235)
Saint Petersburg, Sankt-Peterburg, Russia
EuroCityClinic ( Site 1230)
Saint Petersburg, Sankt-Peterburg, Russia
First Pavlov State Medical University of Saint Petersburg ( Site 1232)
Saint Petersburg, Sankt-Peterburg, Russia
Almazov National Medical Research Centre ( Site 1233)
Saint Petersburg, Sankt-Peterburg, Russia
Clinical Research Center of specialized types medical care-Oncology ( Site 1205)
Saint Petersburg, Sankt-Peterburg, Russia
N.N.Petrov Research Institute of Oncology-Department of Preclinical and Clinical Research ( Site 1211)
Saint Petersburg, Sankt-Peterburg, Russia
National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1210)
Saint Petersburg, Sankt-Peterburg, Russia
City Clinical Oncology Center ( Site 1237)
Saint Petersburg, Sankt-Peterburg, Russia
GBUZ SK Pyatigorsk Interdistrict Oncology dispensary ( Site 1223)
Pyatigorsk, Stavropol Kray, Russia
Republican Clinical Oncology Dispensary ( Site 1228)
Kazan', Tatarstan, Respublika, Russia
Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 1203)
Kazan', Tatarstan, Respublika, Russia
Tomsk Scientific Research Institute of Oncology ( Site 1227)
Tomsk, Tomsk Oblast, Russia
SAIH of the Tyumen region, Multidisciplinary Clinical Medical Center "Medical town" ( Site 1220)
Tyumen, Tyumen Oblast, Russia
Udmurtian Republican Clinical Oncology Center ( Site 1212)
Izhevsk, Udmurtiya Republic, Russia
Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1243)
Yaroslavl, Yaroslavl Oblast, Russia
National Cancer Centre Singapore ( Site 2200)
Singapore, Central Singapore, Singapore
National University Hospital-Haematology -Oncology Research Group ( Site 2201)
Singapore, South West, Singapore
WCR Office ( Site 2002)
Johannesburg, Gauteng, South Africa
Wilgers Oncology Centre ( Site 2006)
Pretoria, Gauteng, South Africa
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2005)
Pretoria, Gauteng, South Africa
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 2004)
Sandton, Gauteng, South Africa
The Oncology Centre ( Site 2000)
Durban, KwaZulu-Natal, South Africa
Cape Town Oncology Trials ( Site 2007)
Cape Town, Western Cape, South Africa
GVI Oncology ( Site 2008)
George, Western Cape, South Africa
Gachon University Gil Medical Center ( Site 0967)
Inceon, Incheon, South Korea
Chonnam National University Hwasun Hospital-Hemato-Oncology ( Site 0959)
Hwasun, Jeonranamdo, South Korea
National Cancer Center ( Site 0955)
Goyang-si, Kyonggi-do, South Korea
CHA Bundang Medical Center CHA University ( Site 0957)
Seongnam-si, Kyonggi-do, South Korea
Seoul National University Bundang Hospital ( Site 0951)
Seongnam-si, Kyonggi-do, South Korea
The Catholic University Of Korea St. Vincent's Hospital ( Site 0968)
Suwon, Kyonggi-do, South Korea
Ajou University Hospital ( Site 0969)
Suwon, Kyonggi-do, South Korea
Chungbuk National University Hospital ( Site 0961)
Cheongju-si, North Chungcheong, South Korea
Gangnam Severance Hospital, Yonsei University Health System ( Site 0966)
Gangnam-gu, Seoul, South Korea
Asan Medical Center ( Site 0952)
Songpagu, Seoul, South Korea
Keimyung University Dongsan Hospital CRC room 1 ( Site 0960)
Daegu, Taegu-Kwangyokshi, South Korea
Kyungpook National University Chilgok Hospital ( Site 0964)
Deagu, Taegu-Kwangyokshi, South Korea
Chungnam national university hospital-Department of Internal Medicine ( Site 0958)
Daejeon, Taejon-Kwangyokshi, South Korea
Korea University Anam Hospital ( Site 0956)
Seoul, , South Korea
Seoul National University Hospital ( Site 0953)
Seoul, , South Korea
Severance Hospital ( Site 0954)
Seoul, , South Korea
Severance Hospital, Yonsei University Health System ( Site 0962)
Seoul, , South Korea
Samsung Medical Center ( Site 0950)
Seoul, , South Korea
Samsung Medical Center ( Site 0970)
Seoul, , South Korea
Korea University Guro Hospital ( Site 0963)
Seoul, , South Korea
Hospital Universitario Virgen de la Victoria ( Site 0878)
Málaga, Andalusia, Spain
Hospital Universitari Son Espases-Oncologia ( Site 0883)
Palma, Balearic Islands, Spain
Hospital Son Llatzer ( Site 0886)
Palma de Mallorca, Balearic Islands, Spain
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0860)
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario de Donostia ( Site 0890)
San Sebastian- Donostia, Basque Country, Spain
H. Marques de Valdecilla ( Site 0865)
Santander, Cantabria, Spain
Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0851)
Badalona, Catalonia, Spain
Hospital Clinic de Barcelona ( Site 0852)
Barcelona, Catalonia, Spain
Hospital de la Santa Creu i Sant Pau-Oncología Médica ( Site 0862)
Barcelona, Catalonia, Spain
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 0876)
Santiago de Compostela, La Coruna, Spain
Hospital Universitario Insular de Gran Canaria ( Site 0867)
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Universitario Puerta de Hierro-Majadahonda ( Site 0861)
Majadahonda, Madrid, Spain
Hospital Universitario Quiron Madrid ( Site 0868)
Pozuelo de Alarcón, Madrid, Spain
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0877)
Madrid, Madrid, Comunidad de, Spain
H.R.U Malaga - Hospital General ( Site 0884)
Málaga, Malaga, Spain
Hospital Universitario Central de Asturias-Medical Oncology ( Site 0870)
Oviedo, Principality of Asturias, Spain
Hospital Universitari Sant Joan de Reus-Oncology ( Site 0874)
Reus, Tarragona, Spain
Hospital Universitari i Politecnic La Fe ( Site 0875)
Valencia, Valencia, Spain
Instituto Valenciano de Oncologia - IVO ( Site 0863)
Valencia, Valenciana, Comunitat, Spain
Hospital Clinico de Valencia ( Site 0858)
Valencia, Valenciana, Comunitat, Spain
Hospital General Universitario de Valencia ( Site 0854)
Valencia, Valenciana, Comunitat, Spain
Hospital Arnau de Vilanova ( Site 0866)
Valencia, Valenciana, Comunitat, Spain
Hospital General Universitario de Alicante-Oncologia ( Site 0881)
Alicante, , Spain
Parc de Salut Mar - Hospital del Mar-Oncologia ( Site 0873)
Barcelona, , Spain
H.U. Vall de Hebron ( Site 0850)
Barcelona, , Spain
Hospital Universitario Reina Sofia ( Site 0885)
Córdoba, , Spain
Complejo Hospitalario de Jaén-Servicio de Oncología Médica ( Site 0879)
Jaén, , Spain
Hospital Universitario Gregorio Maranon ( Site 0864)
Madrid, , Spain
Clinica Universitaria de Navarra ( Site 0855)
Madrid, , Spain
Hospital Clinico San Carlos ( Site 0857)
Madrid, , Spain
Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 0871)
Madrid, , Spain
Hospital General Universitario 12 de Octubre ( Site 0856)
Madrid, , Spain
Hospital Universitario La Paz ( Site 0853)
Madrid, , Spain
Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, ( Site 0869)
Madrid, , Spain
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 0880)
Seville, , Spain
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 0872)
Seville, , Spain
Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 0882)
Seville, , Spain
Hospital Clinico Universitario Lozano Blesa ( Site 0859)
Zaragoza, , Spain
Karolinska Universitetssjukhuset Solna ( Site 0802)
Stockholm, Stockholm County, Sweden
Blod och Tumorssjukdomar. Akademiska sjukhuset ( Site 0801)
Uppsala, Uppsala County, Sweden
Norrlands Universitetssjukhus ( Site 0800)
Umeå, Västerbotten County, Sweden
Sahlgrenska Universitetssjukhuset-Department of Oncology CTU Clinical Trial Unit ( Site 0803)
Gothenburg, Västra Götaland County, Sweden
University Hospital Basel ( Site 0752)
Basel, Canton of Basel-City, Switzerland
Hôpitaux Universitaires de Genève (HUG) ( Site 0753)
Geneva, Canton of Geneva, Switzerland
Universitaetsspital Zuerich ( Site 0750)
Zürich-Flughafen, Canton of Zurich, Switzerland
Kaohsiung Chang Gung Memorial Hospital ( Site 3203)
Kaohsiung City, , Taiwan
China Medical University Hospital ( Site 3204)
Taichung, , Taiwan
National Cheng Kung University Hospital ( Site 3201)
Tainan, , Taiwan
National Taiwan University Hospital ( Site 3200)
Taipei, , Taiwan
Mackay Memorial Hospital ( Site 3205)
Taipei, , Taiwan
Taipei Veterans General Hospital ( Site 3202)
Taipei, , Taiwan
Koo Foundation Sun Yat-Sen Cancer Center-Gynecology, Obstetrics, and women's health ( Site 3207)
Taipei, , Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 3206)
Taoyuan District, , Taiwan
Chulalongkorn University ( Site 2363)
Bangkok, Bangkok, Thailand
Ramathibodi Hospital ( Site 2364)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 2365)
Bangkok, Bangkok, Thailand
Faculty of Medicine - Khon Kaen University ( Site 2366)
Muang, Changwat Khon Kaen, Thailand
Songklanagarind Hospital ( Site 2367)
Hat Yai, Changwat Songkhla, Thailand
Acibadem Altunizade Hospital-Oncology ( Site 1317)
Üsküdar /Istanbul, Istanbul, Turkey (Türkiye)
Acibadem Adana Hospital-Pediatric Hematology-Oncology ( Site 1312)
Adana, , Turkey (Türkiye)
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1307)
Adana, , Turkey (Türkiye)
Adana Sehir Egitim ve Arastirma Hastanesi ( Site 1324)
Adana, , Turkey (Türkiye)
Ankara University Hospital Cebeci ( Site 1306)
Ankara, , Turkey (Türkiye)
Hacettepe Universitesi-oncology hospital ( Site 1304)
Ankara, , Turkey (Türkiye)
Gazi University Health Research and Application Center Gazi Hospital ( Site 1325)
Ankara, , Turkey (Türkiye)
Ankara City Hospital-Medical Oncology ( Site 1311)
Ankara, , Turkey (Türkiye)
Baskent Universitesi Ankara Hastanesi ( Site 1303)
Ankara, , Turkey (Türkiye)
Akdeniz Universitesi Hastanesi-Medical Onkology ( Site 1318)
Antalya, , Turkey (Türkiye)
Memorial Antalya Hospital-Oncology ( Site 1315)
Antalya, , Turkey (Türkiye)
Trakya Universitesi Tip Fakultesi ( Site 1301)
Edirne, , Turkey (Türkiye)
Bezmialem Vakf Üniversitesi-Oncology ( Site 1308)
Istanbul, , Turkey (Türkiye)
Istanbul University Capa Campus ( Site 1314)
Istanbul, , Turkey (Türkiye)
Medipol Mega Universite Hastanesi ( Site 1326)
Istanbul, , Turkey (Türkiye)
Acibadem Universitesi Atakent Hastanesi ( Site 1319)
Istanbul, , Turkey (Türkiye)
Acıbadem Maslak Hastanesi-Medical Oncology ( Site 1321)
Istanbul, , Turkey (Türkiye)
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1302)
Istanbul, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1316)
Istanbul, , Turkey (Türkiye)
Marmara Universitesi Pendik Egitim Arastirma Hastanesi-Medical Oncology ( Site 1305)
Istanbul, , Turkey (Türkiye)
Ege Universitesi Tip Fakultesi Hastanesi ( Site 1300)
Izmir, , Turkey (Türkiye)
Dokuz Eylul Universitesi Hastanesi ( Site 1323)
Izmir, , Turkey (Türkiye)
I.E.U. Medical Point Hastanesi-Oncology ( Site 1310)
Izmir, , Turkey (Türkiye)
Kocaeli Üniversitesi ( Site 1313)
Kocaeli, , Turkey (Türkiye)
Inonu Universitesi ( Site 1309)
Malatya, , Turkey (Türkiye)
ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 3668)
Dnipro, Dnipropetrovsk Oblast, Ukraine
Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council ( Site 3650)
Dnipro, Dnipropetrovsk Oblast, Ukraine
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional-Chemotherapy department ( Site 3657)
Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine
Communal Non-Commercial Enterprise "Prykarpatski Clinical Oncological Center" of Ivano-Frankivsk Reg ( Site 3663)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
MNPE Regional Center of Oncology ( Site 3665)
Kharkiv, Kharkivs’ka Oblast’, Ukraine
SO"Grigoriev Inst for Med Radiolgy and Oncology of NAMS of Ukraine" ( Site 3666)
Kharlkiv, Kharkivs’ka Oblast’, Ukraine
Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 3656)
Kropyvnytskyi, Kirovohrad Oblast, Ukraine
Asklepion Medical Center ( Site 3667)
Khodosovka, Kyivska Oblast, Ukraine
National Cancer Institute-Department of Minimally Invasive and Endoscopic Surgery, Interventional R ( Site 3658)
Kyiv, Kyivska Oblast, Ukraine
LLC Clinic Verum Expert ( Site 3669)
Kyiv, Kyivska Oblast, Ukraine
Municipal non-profit enterprise "Kyiv City Clinical Oncology Center" of executive body of Kyiv City ( Site 3651)
Kyiv, Kyivska Oblast, Ukraine
Municipal institution of Lviv regional council Lviv Oncology-Chemotherapy ( Site 3653)
Lviv, Lviv Oblast, Ukraine
Odessa Regional Oncology Center ( Site 3655)
Odesa, Odesa Oblast, Ukraine
Sumy regional clinical oncological dispensary-Oncothoracic department ( Site 3661)
Sumy, Sumska Oblast, Ukraine
Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 3662)
Vinnytsia, Vinnytsia Oblast, Ukraine
Transcarpathian Regional Clinical Oncology Center-Chemotherapy dept. ( Site 3652)
Uzhhorod, Zakarpattia Oblast, Ukraine
Municipal non-profit enterprise "Zaporizhzhia regional clinical hospital" of Zaporizhzhia regional c ( Site 3664)
Zaporizhzhia, Zaporizhzhia Oblast, Ukraine
Aberdeen Royal Infirmary-Department of Oncology ( Site 0521)
Aberdeen, Aberdeen City, United Kingdom
Addenbrookes Hospital ( Site 0522)
Cambridge, Cambridgeshire, United Kingdom
Western General Hospital ( Site 0502)
Edinburgh, Edinburgh, City of, United Kingdom
The Christie ( Site 0516)
Manchester, England, United Kingdom
Weston Park Hospital ( Site 0519)
Sheffield, England, United Kingdom
Mid Essex Hospitals Service Trust. Broomfield Hospital ( Site 0503)
Broomfield, Essex, United Kingdom
The Beatson West of Scotland Cancer Centre ( Site 0506)
Glasgow, Glasgow City, United Kingdom
Royal Preston Hospital ( Site 0518)
Preston, Lancashire, United Kingdom
Barts Health NHS Trust ( Site 0512)
London, London, City of, United Kingdom
University College London Hospital-Cancer Clinical Trials Unit ( Site 0520)
London, London, City of, United Kingdom
Royal Free Hospital ( Site 0507)
London, London, City of, United Kingdom
Royal Marsden Hospital ( Site 0505)
London, London, City of, United Kingdom
Sarah Cannon Research UK ( Site 0504)
London, London, City of, United Kingdom
Belfast City Hospital ( Site 0508)
Belfast, Northern Ireland, United Kingdom
Nottingham University Hospitals NHS Trust ( Site 0510)
Nottingham, Nottinghamshire, United Kingdom
University Hospital Coventry & Warwickshire ( Site 0524)
Coventry, , United Kingdom
St James University Hospital ( Site 0509)
Leeds, , United Kingdom
The Royal Marsden NHS Foundation Trust. ( Site 0513)
Sutton, , United Kingdom
New Cross Hospital-Department of Oncology ( Site 0517)
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J Clin Oncol. 2023 Aug 20;41(24):3998-4003. doi: 10.1200/JCO.22.01599. Epub 2023 Jun 22.
Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024 Dec;35(12):1191-1199. doi: 10.1016/j.annonc.2024.08.2330. Epub 2024 Sep 15.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-3475-587
Identifier Type: OTHER
Identifier Source: secondary_id
KEYNOTE-587
Identifier Type: OTHER
Identifier Source: secondary_id
195006
Identifier Type: REGISTRY
Identifier Source: secondary_id
PHRR210209-002881
Identifier Type: REGISTRY
Identifier Source: secondary_id
2022-501254-10-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
jRCT2080224921
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1274-2274
Identifier Type: REGISTRY
Identifier Source: secondary_id
2017-004417-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
3475-587
Identifier Type: -
Identifier Source: org_study_id